Table 2.
Trends in Molecular Testing of NSCLC in Selected Hospitals During 2010 to 2019 in Mainland People’s Republic of China
| Driver Gene | Sample Type | Methods | 2010 | 2011 | No. and Proportion of Molecular Testing of the Total NSCLC Cases, by Year |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | |||||
| Total cases | N = 1372 | N = 2177 | N = 5034 | N = 9414 | N = 15,621 | N = 22,718 | N = 30,719 | N = 39,251 | N = 46,514 | N = 53,407 | ||
| EGFR | FFPE | qRT-PCR | 659 (48.0) | 1461 (67.1) | 4582 (91) | 8565 (90.9) | 14,490 (92.7) | 21,280 (93.6) | 28,991 (94.4) | 37,131 (94.6) | 36,292 (78.0) | 36,918 (69.1) |
| NGS | — | — | — | — | — | 132 (0.6) | 754 (2.5) | 2870 (7.3) | 8222 (17.7) | 11,783 (22.1) | ||
| Sanger sequencing | 713 (51.9) | 672 (30.8) | — | — | — | — | — | — | — | — | ||
| EGFR | Blood | Super-ARMS | — | — | — | — | 46 (0.3) | 282 (1.2) | 836 (2.7) | 1276 (3.3) | 1770 (3.8) | 2430 (4.5) |
| NGS | — | — | — | — | — | — | 47 (0.2) | 683 (1.7) | 1260 (2.7) | 1790 (3.4) | ||
| ALK | FFPE | qRT-PCR | — | — | 23 (0.5) | 317 (3.4) | 787 (5.0) | 1845 (8.1) | 2996 (9.8) | 4999 (12.7) | 9973 (21.4) | 16,384 (30.7) |
| FISH | 88 (6.4) | 336 (15.4) | 537 (10.7) | 1879 (20.0) | 2932 (18.8) | 4796 (21.1) | 5095 (17.6) | 6502 (16.6) | 6874 (14.8) | 5726 (10.7) | ||
| Vetana-D5F3 IHC | — | — | — | 502 (5.3) | 4110 (26.3) | 4574 (20.1) | 8313 (27.1) | 12,063 (30.7) | 7525 (16.2) | 10,753 (20.1) | ||
| NGS | — | — | — | — | — | 132 (0.6) | 759 (2.5) | 2610 (6.6) | 8145 (17.5) | 10,346 (19.4) | ||
| ROS1 | FFPE | qRT-PCR | — | — | 2 (0.0) | 140 (1.5) | 177 (1.1) | 502 (2.2) | 1330 (4.3) | 4562 (11.6) | 9581 (20.6) | 15,847 (29.7) |
| FISH | — | — | — | — | 226 (1.4) | 1394 (6.1) | 1792 (5.8) | 3890 (9.9) | 4644 (10.0) | 4311 (8.1) | ||
| NGS | — | — | — | — | — | 191 (0.8) | 754 (2.5) | 2605 (6.6) | 7528 (16.2) | 10,339 (19.4) | ||
Note: Values are given in n (%).
FFPE, formalin-fixed, paraffin-embedded; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NGS, next-generation sequencing; qRT-PCR, quantitative reverse-transcriptase polymerase chain reaction; Super-AMRS, superamplification-amplification refractory mutation system.